Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
623 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Melanoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H2 2015', provides an overview of the Metastatic Melanoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Metastatic Melanoma Overview 12 Therapeutics Development 13 Pipeline Products for Metastatic Melanoma - Overview 13 Pipeline Products for Metastatic Melanoma - Comparative Analysis 14 Metastatic Melanoma - Therapeutics under Development by Companies 15 Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 19 Metastatic Melanoma - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Metastatic Melanoma - Products under Development by Companies 24 Metastatic Melanoma - Products under Investigation by Universities/Institutes 29 Metastatic Melanoma - Companies Involved in Therapeutics Development 30 AB Science SA 30 AbbVie Inc. 31 Adaptimmune Limited 32 Affichem SA 33 Agalimmune Ltd 34 Agenus, Inc. 35 AGV Discovery, SAS 36 Altor BioScience Corporation 37 Amgen Inc. 38 Arisaph Pharmaceuticals, Inc. 39 Array BioPharma Inc. 40 Astex Pharmaceuticals, Inc. 41 AstraZeneca Plc 42 Basilea Pharmaceutica AG 43 Bioncotech Therapeutics S.L. 44 Bionomics Limited 45 Boehringer Ingelheim GmbH 46 Bristol-Myers Squibb Company 47 Caladrius Biosciences, Inc. 48 cCAM Biotherapeutics Ltd. 49 Cellceutix Corporation 50 Celldex Therapeutics, Inc. 51 Delcath Systems, Inc. 52 Digna Biotech, S.L. 53 DNA Therapeutics S.A. 54 Dynavax Technologies Corporation 55 Eisai Co., Ltd. 56 Eli Lilly and Company 57 Ensol Biosciences Inc. 58 F. Hoffmann-La Roche Ltd. 59 Galapagos NV 60 Galectin Therapeutics, Inc. 61 GlaxoSmithKline Plc 62 Idera Pharmaceuticals, Inc. 63 Immune Design Corp. 64 ImmuRx, Inc. 65 Incyte Corporation 66 IO Biotech ApS 67 Life Science Pharmaceuticals, Incorporated 68 Lipotek Pty Ltd. 69 Luitpold Pharmaceuticals, Inc. 70 MacroGenics, Inc. 71 MedImmune, LLC 72 Medivation, Inc. 73 MELEMA Pharma GmbH 74 Memgen, LLC. 75 Merck & Co., Inc. 76 Merck KGaA 77 Millennium Pharmaceuticals, Inc. 78 Morphotek, Inc. 79 NewLink Genetics Corporation 80 Novartis AG 81 Omeros Corporation 82 Oncolytics Biotech Inc. 83 OncoSec Medical Inc. 84 Ono Pharmaceutical Co., Ltd. 85 Pfizer Inc. 86 Pharmis Biofarmaceutica, Lda. 87 Philogen S.p.A. 88 Plexxikon Inc. 89 Polaris Pharmaceuticals, Inc. 90 Polyphor Ltd. 91 Prima BioMed Ltd. 92 Provectus Biopharmaceuticals, Inc. 93 Provenance Biopharmaceuticals Corp. 94 Reata Pharmaceuticals, Inc. 95 RXi Pharmaceuticals Corporation 96 Scancell Holdings Plc 97 Syndax Pharmaceuticals, Inc. 98 Takara Bio Inc. 99 TC BioPharm Limited 100 Tikcro Technologies, Ltd. 101 Ultimovacs AS 102 Metastatic Melanoma - Therapeutics Assessment 103 Assessment by Monotherapy Products 103 Assessment by Combination Products 104 Assessment by Target 105 Assessment by Mechanism of Action 114 Assessment by Route of Administration 120 Assessment by Molecule Type 122 Drug Profiles 124 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 124 A-dmDT390-bisFv - Drug Profile 126 abemaciclib - Drug Profile 127 AF-122 - Drug Profile 129 AGI-134 - Drug Profile 130 ALT-801 - Drug Profile 131 ALT-803 - Drug Profile 134 AMG-232 - Drug Profile 136 Anti-CSPG4-IL2 - Drug Profile 137 Antibody to Inhibit HSP90 for Metastatic Melanoma - Drug Profile 138 ARI-4175 - Drug Profile 139 atezolizumab - Drug Profile 141 austrasulfone - Drug Profile 145 aviscumine - Drug Profile 146 BAL-3833 - Drug Profile 148 bevacizumab - Drug Profile 149 binimetinib + encorafenib - Drug Profile 155 BL-011256 - Drug Profile 157 BNC-420 - Drug Profile 158 BO-110 - Drug Profile 159 buparlisib hydrochloride - Drug Profile 160 cancer vaccine - Drug Profile 164 capmatinib - Drug Profile 165 CB-745 - Drug Profile 168 Cellular Immunotherapy 1 for Metastatic Melanoma - Drug Profile 169 Cellular Immunotherapy 2 for Metastatic Melanoma - Drug Profile 170 Cellular Immunotherapy 2 for Metastatic Melanoma - Drug Profile 171 Cellular Immunotherapy for Cancer and Viral Infections - Drug Profile 172 Cellular Immunotherapy for Metastatic Melanoma - Drug Profile 174 Cellular Immunotherapy for Metastatic Melanoma - Drug Profile 175 Cellular Immunotherapy to Target HERV-K for Metastatic Melanoma - Drug Profile 177 Cellular Immunotherapy to Target MAGE-A6, MART-1 and Tyrosinase for Metastatic Melanoma - Drug Profile 178 Cellular Immunotherapy to Target MART-1 and MELOE-1 for Metastatic Melanoma - Drug Profile 179 Cellular Immunotherapy to Target MART-1 for Metastatic Melanoma - Drug Profile 180 Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanoma - Drug Profile 181 Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile 182 Charis-1000 - Drug Profile 183 CM-24 - Drug Profile 184 dabrafenib mesylate - Drug Profile 185 dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 188 Darleukin - Drug Profile 189 DB-039 - Drug Profile 191 diphencyprone - Drug Profile 192 DNA IL-12 - Drug Profile 193 Drugs to Antagonize ETBR for Metastatic Melanoma - Drug Profile 196 DT-01 - Drug Profile 197 E-6201 - Drug Profile 199 ecromeximab - Drug Profile 201 eltrapuldencel-T - Drug Profile 202 encorafenib - Drug Profile 205 enoblituzumab - Drug Profile 207 entinostat - Drug Profile 209 epacadostat - Drug Profile 213 FC-311 - Drug Profile 215 G-305 - Drug Profile 216 glembatumumab vedotin - Drug Profile 218 GLPG-1790 - Drug Profile 220 GRMD-02 - Drug Profile 221 GSK-2241658A - Drug Profile 224 GSK-2302025A - Drug Profile 225 GSK-3377794 - Drug Profile 226 guadecitabine - Drug Profile 228 HF-10 - Drug Profile 232 ICOVIR-5 - Drug Profile 234 IMO-2125 - Drug Profile 235 IMP-321 - Drug Profile 237 indoximod - Drug Profile 239 IO-102 - Drug Profile 241 ISF-35 - Drug Profile 242 KM-3174 - Drug Profile 244 lenvatinib - Drug Profile 248 lirilumab - Drug Profile 254 LN-144 - Drug Profile 256 LOC-paclitaxel - Drug Profile 259 LV-305 - Drug Profile 260 LY-3009120 - Drug Profile 261 M-200 - Drug Profile 262 masitinib - Drug Profile 263 MEDI-3617 - Drug Profile 269 melphalan - Drug Profile 270 miRNA-7-5p - Drug Profile 273 MK-0429 - Drug Profile 274 Monoclonal Antibodies to Antagonise PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 275 Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma - Drug Profile 276 Monoclonal Antibody to Inhibit CD40 for Metastatic Melanoma - Drug Profile 277 MORAb-050 - Drug Profile 278 navitoclax dihydrochloride - Drug Profile 279 nilotinib - Drug Profile 281 nintedanib - Drug Profile 285 nivolumab - Drug Profile 290 omaveloxolone - Drug Profile 298 onalespib - Drug Profile 301 ontuxizumab - Drug Profile 304 palbociclib - Drug Profile 306 panobinostat - Drug Profile 310 pasireotide - Drug Profile 316 PDC-mel - Drug Profile 319 pegargiminase - Drug Profile 320 pelareorep - Drug Profile 324 pembrolizumab - Drug Profile 329 pexidartinib - Drug Profile 338 pidilizumab - Drug Profile 340 pimasertib hydrochloride - Drug Profile 342 POL-7085 - Drug Profile 345 PV-10 - Drug Profile 346 Q-122 - Drug Profile 350 Q-204 - Drug Profile 352 RAF-265 - Drug Profile 353 Recombinant Protein for Metastatic Melanoma - Drug Profile 354 Recombinant Protein for Oncology - Drug Profile 355 ribociclib - Drug Profile 356 SCIB-1 - Drug Profile 359 SD-101 - Drug Profile 362 Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer - Drug Profile 364 Small Molecules to Antagonize ET-B for Oncology - Drug Profile 365 Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile 366 Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Cancer - Drug Profile 367 SRX-1177 - Drug Profile 368 sunitinib malate - Drug Profile 369 TAK-580 - Drug Profile 373 talimogene laherparepvec - Drug Profile 375 TMECG - Drug Profile 378 TPI-287 - Drug Profile 379 trametinib dimethyl sulfoxide - Drug Profile 381 tremelimumab + MEDI-3617 - Drug Profile 384 UV-1 - Drug Profile 385 Vaccine for Metastatic Melanoma - Drug Profile 386 varlilumab - Drug Profile 387 veliparib - Drug Profile 389 vemurafenib - Drug Profile 393 ZSG-101 - Drug Profile 397 ZSG-102 - Drug Profile 398 Metastatic Melanoma - Recent Pipeline Updates 399 Metastatic Melanoma - Dormant Projects 586 Metastatic Melanoma - Discontinued Products 599 Metastatic Melanoma - Product Development Milestones 601 Featured News & Press Releases 601 Appendix 613 Methodology 613 Coverage 613 Secondary Research 613 Primary Research 613 Expert Panel Validation 613 Contact Us 613 Disclaimer 614
List of Tables
Number of Products under Development for Metastatic Melanoma, H2 2015 22 Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2015 23 Number of Products under Development by Companies, H2 2015 25 Number of Products under Development by Companies, H2 2015 (Contd..1) 26 Number of Products under Development by Companies, H2 2015 (Contd..2) 27 Number of Products under Investigation by Universities/Institutes, H2 2015 29 Comparative Analysis by Late Stage Development, H2 2015 30 Comparative Analysis by Clinical Stage Development, H2 2015 31 Comparative Analysis by Early Stage Development, H2 2015 32 Products under Development by Companies, H2 2015 33 Products under Development by Companies, H2 2015 (Contd..1) 34 Products under Development by Companies, H2 2015 (Contd..2) 35 Products under Development by Companies, H2 2015 (Contd..3) 36 Products under Development by Companies, H2 2015 (Contd..4) 37 Products under Investigation by Universities/Institutes, H2 2015 38 Metastatic Melanoma - Pipeline by AB Science SA, H2 2015 39 Metastatic Melanoma - Pipeline by AbbVie Inc., H2 2015 40 Metastatic Melanoma - Pipeline by Adaptimmune Limited, H2 2015 41 Metastatic Melanoma - Pipeline by Affichem SA, H2 2015 42 Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2015 43 Metastatic Melanoma - Pipeline by Agenus, Inc., H2 2015 44 Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H2 2015 45 Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H2 2015 46 Metastatic Melanoma - Pipeline by Amgen Inc., H2 2015 47 Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015 48 Metastatic Melanoma - Pipeline by Array BioPharma Inc., H2 2015 49 Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 50 Metastatic Melanoma - Pipeline by AstraZeneca Plc, H2 2015 51 Metastatic Melanoma - Pipeline by Basilea Pharmaceutica AG, H2 2015 52 Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H2 2015 53 Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2015 54 Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 55 Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 56 Metastatic Melanoma - Pipeline by Caladrius Biosciences, Inc. , H2 2015 57 Metastatic Melanoma - Pipeline by cCAM Biotherapeutics Ltd., H2 2015 58 Metastatic Melanoma - Pipeline by Cellceutix Corporation, H2 2015 59 Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 60 Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2015 61 Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2015 62 Metastatic Melanoma - Pipeline by DNA Therapeutics S.A., H2 2015 63 Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H2 2015 64 Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2015 65 Metastatic Melanoma - Pipeline by Eli Lilly and Company, H2 2015 66 Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H2 2015 67 Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 68 Metastatic Melanoma - Pipeline by Galapagos NV, H2 2015 69 Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2015 70 Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2015 71 Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 72 Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2015 73 Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2015 74 Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2015 75 Metastatic Melanoma - Pipeline by IO Biotech ApS, H2 2015 76 Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2015 77 Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2015 78 Metastatic Melanoma - Pipeline by Luitpold Pharmaceuticals, Inc., H2 2015 79 Metastatic Melanoma - Pipeline by MacroGenics, Inc., H2 2015 80 Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2015 81 Metastatic Melanoma - Pipeline by Medivation, Inc., H2 2015 82 Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH , H2 2015 83 Metastatic Melanoma - Pipeline by Memgen, LLC., H2 2015 84 Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2015 85 Metastatic Melanoma - Pipeline by Merck KGaA, H2 2015 86 Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 87 Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2015 88 Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H2 2015 89 Metastatic Melanoma - Pipeline by Novartis AG, H2 2015 90 Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2015 91 Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2015 92 Metastatic Melanoma - Pipeline by OncoSec Medical Inc., H2 2015 93 Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 94 Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2015 95 Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H2 2015 96 Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2015 97 Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2015 98 Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 99 Metastatic Melanoma - Pipeline by Polyphor Ltd., H2 2015 100 Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H2 2015 101 Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015 102 Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H2 2015 103 Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H2 2015 104 Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 105 Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2015 106 Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 107 Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2015 108 Metastatic Melanoma - Pipeline by TC BioPharm Limited, H2 2015 109 Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H2 2015 110 Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2015 111 Assessment by Monotherapy Products, H2 2015 112 Assessment by Combination Products, H2 2015 113 Number of Products by Stage and Target, H2 2015 115 Number of Products by Stage and Mechanism of Action, H2 2015 124 Number of Products by Stage and Route of Administration, H2 2015 130 Number of Products by Stage and Molecule Type, H2 2015 132 Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H2 2015 408 Metastatic Melanoma - Dormant Projects, H2 2015 595 Metastatic Melanoma - Dormant Projects (Contd..1), H2 2015 596 Metastatic Melanoma - Dormant Projects (Contd..2), H2 2015 597 Metastatic Melanoma - Dormant Projects (Contd..3), H2 2015 599 Metastatic Melanoma - Dormant Projects (Contd..4), H2 2015 600 Metastatic Melanoma - Dormant Projects (Contd..5), H2 2015 601 Metastatic Melanoma - Dormant Projects (Contd..6), H2 2015 602 Metastatic Melanoma - Dormant Projects (Contd..7), H2 2015 603 Metastatic Melanoma - Dormant Projects (Contd..8), H2 2015 604 Metastatic Melanoma - Dormant Projects (Contd..9), H2 2015 605 Metastatic Melanoma - Dormant Projects (Contd..10), H2 2015 606 Metastatic Melanoma - Dormant Projects (Contd..11), H2 2015 607 Metastatic Melanoma - Discontinued Products, H2 2015 608 Metastatic Melanoma - Discontinued Products (Contd..1), H2 2015 609
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
